On the public citation graph

Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

0 signed · 411 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

1 of the 60 references listed on this page is in the Retraction Watch database as retracted (export 2026-11-18): 10.1210/jc.2014-2739 (notice 2015-05-01).

Dataset join, best-effort; this page does not check the publisher record. Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0); dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/dmrr.3157openalex-snapshot
Prevalence of diabetes in liver cirrhosis: A systematic review and meta‐analysis
inferredcites →https://doi.org/10.1002/hep.21327openalex-snapshot
Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡
inferredcites →https://doi.org/10.1002/hep.26156openalex-snapshot
Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States
inferredcites →https://doi.org/10.1002/hep.27981openalex-snapshot
Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study
inferredcites →https://doi.org/10.1002/hep.28958openalex-snapshot
Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost‐effectiveness analysis
inferredcites →https://doi.org/10.1002/hep.28985openalex-snapshot
Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1002/hep.29367openalex-snapshot
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
inferredcites →https://doi.org/10.1002/hep.29489openalex-snapshot
Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1002/hep.30670openalex-snapshot
Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes
inferredcites →https://doi.org/10.1002/hep4.1054openalex-snapshot
Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1002/hep4.1195openalex-snapshot
Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes
inferredcites →https://doi.org/10.1007/s00125-016-3902-yopenalex-snapshot
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
inferredcites →https://doi.org/10.1007/s00535-019-01626-1openalex-snapshot
Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease
inferredcites →https://doi.org/10.1007/s11695-015-1691-xopenalex-snapshot
Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology
inferredcites →https://doi.org/10.1016/j.amjmed.2020.01.007openalex-snapshot
Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
inferredcites →https://doi.org/10.1016/j.cgh.2008.03.005openalex-snapshot
Screening for Liver Fibrosis by Using a Noninvasive Biomarker in Patients With Diabetes
inferredcites →https://doi.org/10.1016/j.cgh.2017.12.001openalex-snapshot
Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes
inferredcites →https://doi.org/10.1016/j.cgh.2018.11.004openalex-snapshot
Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1016/j.cgh.2018.11.011openalex-snapshot
FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage
inferredcites →https://doi.org/10.1016/j.cgh.2018.12.031openalex-snapshot
Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage
inferredcites →https://doi.org/10.1016/j.diabet.2019.11.004openalex-snapshot
Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes
inferredcites →https://doi.org/10.1016/j.jhep.2013.04.027openalex-snapshot
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
inferredcites →https://doi.org/10.1016/j.jhep.2013.10.017openalex-snapshot
Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: The Edinburgh type 2 diabetes study
inferredcites →https://doi.org/10.1016/j.jhep.2015.11.004openalex-snapshot
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
inferredcites →https://doi.org/10.1016/j.jhep.2017.11.012openalex-snapshot
Determinants of fibrosis progression and regression in NASH
inferredcites →https://doi.org/10.1016/j.jhep.2019.06.021openalex-snapshot
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/j.jhep.2020.06.025openalex-snapshot
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
inferredcites →https://doi.org/10.1016/j.jhepr.2019.07.002openalex-snapshot
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
inferredcites →https://doi.org/10.1016/s0399-8320(08)73994-0openalex-snapshot
Transient elastography (FibroScan)
inferredcites →https://doi.org/10.1016/s0739-5930(09)79298-0openalex-snapshot
Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1016/s2213-8587(18)30154-2openalex-snapshot
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
inferredcites →https://doi.org/10.1038/s41591-018-0104-9openalex-snapshot
Mechanisms of NAFLD development and therapeutic strategies
inferredcites →https://doi.org/10.1053/j.gastro.2008.06.047openalex-snapshot
Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1053/j.gastro.2012.02.003openalex-snapshot
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
inferredcites →https://doi.org/10.1053/j.gastro.2018.12.036openalex-snapshot
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1053/j.gastro.2019.01.042openalex-snapshot
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1053/j.gastro.2020.01.043openalex-snapshot
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
inferredcites →https://doi.org/10.1055/a-0984-5753openalex-snapshot
Diabetes and Fatty Liver
inferredcites →https://doi.org/10.1056/nejmoa060326openalex-snapshot
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1056/nejmoa0907929openalex-snapshot
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1080/13543784.2020.1721169openalex-snapshot
NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges
inferredcites →https://doi.org/10.1097/md.0000000000011518openalex-snapshot
Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis
inferredcites →https://doi.org/10.1111/apt.13405openalex-snapshot
Non‐invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE
inferredcites →https://doi.org/10.1111/dom.12973openalex-snapshot
Non‐alcoholic fatty liver disease ( NAFLD ) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes
inferredcites →https://doi.org/10.1111/jgh.14577openalex-snapshot
Screening for non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography
inferredcites →https://doi.org/10.1111/liv.12840openalex-snapshot
Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients
inferredcites →https://doi.org/10.1136/gutjnl-2015-309265openalex-snapshot
Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study
inferredcites →https://doi.org/10.1136/gutjnl-2020-320622openalex-snapshot
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
inferredcites →https://doi.org/10.1136/jim-2017-000554openalex-snapshot
Glucagon like Peptide-1 Receptor Agonists for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: A Novel Therapeutic Option
inferredcites →https://doi.org/10.1210/jc.2014-2739openalex-snapshot
WITHDRAWN: High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels (article published in final form as 10.1210/jc.2015-1966)
inferredcites →https://doi.org/10.1210/jc.2015-1966openalex-snapshot
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
inferredcites →https://doi.org/10.1371/journal.pone.0236977openalex-snapshot
Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus
inferredcites →https://doi.org/10.2337/dc19-0167openalex-snapshot
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
inferredcites →https://doi.org/10.2337/dc19-1071openalex-snapshot
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc19-1113openalex-snapshot
Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
inferredcites →https://doi.org/10.2337/dc20-s004openalex-snapshot
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2020
inferredcites →https://doi.org/10.3390/diagnostics10030159openalex-snapshot
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
inferredcites →https://doi.org/10.3390/diseases6040091openalex-snapshot
When to Initiate Weight Loss Medications in the NAFLD Population
inferredcites →https://doi.org/10.3390/jcm9041032openalex-snapshot
Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience
inferredcites →https://doi.org/10.7326/m15-1774openalex-snapshot
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4840179openalex-extracted
The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
inferred← citeshttps://doi.org/10.2139/ssrn.5145948openalex-extracted
High Prevalence of CKM Syndrome in the US and Chinese Population with MASLD
inferred← citeshttps://doi.org/10.1001/jamainternmed.2025.4769openalex-snapshot
Targeting MASLD and MASH in the US Hispanic/Latino Population
inferred← citeshttps://doi.org/10.1002/hep.32244openalex-snapshot
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1002/hep4.1957openalex-snapshot
Interaction of metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019
inferred← citeshttps://doi.org/10.1002/jgh3.12606openalex-snapshot
Prevalence of clinically relevant liver fibrosis due to nonalcoholic fatty liver disease in Indian individuals with type 2 diabetes
inferred← citeshttps://doi.org/10.1002/jgh3.70039openalex-snapshot
Overlapping group between non‐alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research
inferred← citeshttps://doi.org/10.1002/jmv.28239openalex-snapshot
Development and validation of a potential biomarker to improve the assessment of liver fibrosis progression in patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/oby.23263openalex-snapshot
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1002/oby.23422openalex-snapshot
Response to: “Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?”
inferred← citeshttps://doi.org/10.1002/oby.24130openalex-snapshot
Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen
inferred← citeshttps://doi.org/10.1002/poh2.70032openalex-snapshot
Factors Associated With Liver Fibrosis in Patients With Type 2 Diabetes and the Predictive Value of CHI3L1
inferred← citeshttps://doi.org/10.1007/978-3-031-33548-8_14openalex-snapshot
Type 2 Diabetes Mellitus and Insulin Resistance in Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1007/978-3-031-82888-1_10openalex-snapshot
Effects of Lifestyle Interventions on Metabolic Dysfunction-Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1007/978-981-96-3894-9_10openalex-snapshot
Prevention of HCC
inferred← citeshttps://doi.org/10.1007/s00125-024-06087-7openalex-snapshot
Surveillance of the liver in type 2 diabetes: important but unfeasible?
inferred← citeshttps://doi.org/10.1007/s00125-026-06816-0openalex-snapshot
Screening and diagnosis of liver disease in diabetes: a guide and evidence-based assessment
inferred← citeshttps://doi.org/10.1007/s00592-026-02791-5openalex-snapshot
MASLD in type 2 diabetes: steatosis–fibrosis burden and metabolic determinants in a real-world cohort
inferred← citeshttps://doi.org/10.1007/s10620-023-07959-5openalex-snapshot
Gaps in Confirmatory Fibrosis Risk Assessment in Primary Care Patients with Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1007/s10620-023-08186-8openalex-snapshot
Limitations of Noninvasive Tests-Based Population-Level Risk Stratification Strategy for Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1007/s11154-023-09843-zopenalex-snapshot
Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies
inferred← citeshttps://doi.org/10.1007/s11428-026-01456-9openalex-snapshot
Rationale Diagnostik bei metabolischen Lebererkrankungen (MASLD)
inferred← citeshttps://doi.org/10.1007/s11606-025-09348-2openalex-snapshot
Noninvasive Assessment of the Severity of Liver Fibrosis in MASLD Patients with Long-Standing Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/s11606-025-09659-4openalex-snapshot
Diagnosis of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) at Risk for Advanced Fibrosis in a Real-World Primary Care Setting: A Cross-Sectional Study
inferred← citeshttps://doi.org/10.1007/s11739-023-03441-2openalex-snapshot
Accuracy of a sequential algorithm based on FIB-4 and ELF to identify high-risk advanced liver fibrosis at the primary care level
inferred← citeshttps://doi.org/10.1007/s11845-022-03019-5openalex-snapshot
Reduced and more appropriate referrals of patients with type 2 diabetes using liver stiffness measurement compared to FIB-4
inferred← citeshttps://doi.org/10.1007/s11892-024-01558-yopenalex-snapshot
NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
inferred← citeshttps://doi.org/10.1007/s11894-025-00988-2openalex-snapshot
Evolving Role of GLP-1 Therapies in Liver Disease
inferred← citeshttps://doi.org/10.1007/s11901-024-00639-6openalex-snapshot
Endocrinology for the Hepatologist
inferred← citeshttps://doi.org/10.1007/s11901-025-00713-7openalex-snapshot
Transient Elastography and Fibroscan: Stethoscope of a Hepatologist in Today’s World
inferred← citeshttps://doi.org/10.1007/s12011-023-03666-4openalex-snapshot
Associations of Serum Iron Status with MAFLD and Liver Fibrosis in the USA: a Nationwide Cross-Section Study
inferred← citeshttps://doi.org/10.1007/s12072-021-10209-3openalex-snapshot
Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease
inferred← citeshttps://doi.org/10.1007/s12072-023-10625-7openalex-snapshot
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes
inferred← citeshttps://doi.org/10.1007/s13105-026-01141-xopenalex-snapshot
Liver fibrosis and type 2 diabetes modulate postprandial incretin and glucagon responses in fatty liver disease
inferred← citeshttps://doi.org/10.1007/s13410-026-01633-yopenalex-snapshot
Improving stratification of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease patients with type-2 diabetes mellitus in low-resource settings
inferred← citeshttps://doi.org/10.1007/s41969-022-00158-zopenalex-snapshot
Der hepatogene Diabetes – aktueller Stand der Diagnostik und Therapie
inferred← citeshttps://doi.org/10.1016/b978-0-323-99649-5.00003-0openalex-snapshot
Clinical diagnosis and evaluation pathway
inferred← citeshttps://doi.org/10.1016/j.amjms.2023.11.007openalex-snapshot
Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting
inferred← citeshttps://doi.org/10.1016/j.aohep.2022.100892openalex-snapshot
Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease
inferred← citeshttps://doi.org/10.1016/j.aohep.2023.101142openalex-snapshot
Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists
inferred← citeshttps://doi.org/10.1016/j.aohep.2024.101511openalex-snapshot
Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
inferred← citeshttps://doi.org/10.1016/j.aohep.2024.101584openalex-snapshot
FLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease
inferred← citeshttps://doi.org/10.1016/j.aohep.2026.102201openalex-snapshot
Liver transplant outcomes in primary biliary cholangitis and metabolic dysfunction-associated steatotic liver disease overlap
inferred← citeshttps://doi.org/10.1016/j.bbadis.2023.166763openalex-snapshot
The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit
inferred← citeshttps://doi.org/10.1016/j.cgh.2024.01.032openalex-snapshot
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.cgh.2024.03.006openalex-snapshot
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
inferred← citeshttps://doi.org/10.1016/j.cgh.2025.02.018openalex-snapshot
Effectiveness of Six International Guidelines Using Fibrosis-4 and FibroScan for Risk Stratification of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1016/j.cld.2025.04.003openalex-snapshot
The Liver in Diabetes and Metabolic Syndrome
inferred← citeshttps://doi.org/10.1016/j.cld.2025.12.001openalex-snapshot
Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases
inferred← citeshttps://doi.org/10.1016/j.clnu.2024.02.006openalex-snapshot
Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002–2022)
inferred← citeshttps://doi.org/10.1016/j.deman.2023.100161openalex-snapshot
Prevalence of nonalcoholic fatty liver disease in type 2 diabetes mellitus patients from the Eastern region of India
inferred← citeshttps://doi.org/10.1016/j.diabres.2021.108879openalex-snapshot
Current type 2 diabetes, rather than previous gestational diabetes, is associated with liver disease in U.S. Women
inferred← citeshttps://doi.org/10.1016/j.diabres.2021.108922openalex-snapshot
Glycemic variability and the risk of nonalcoholic fatty liver disease : A nationwide population-based cohort study
inferred← citeshttps://doi.org/10.1016/j.diabres.2022.109827openalex-snapshot
Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes
inferred← citeshttps://doi.org/10.1016/j.diabres.2022.109981openalex-snapshot
Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.diabres.2022.110206openalex-snapshot
Fibrosis-4 stage of liver fibrosis predicts cardiovascular outcomes in acute coronary syndrome patients with and without type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1016/j.diabres.2024.111609openalex-snapshot
The hidden epidemic: Uncovering incidental fatty liver disease and its metabolic comorbidities by datamining in a hospital data lake – A real-world cohort study
inferred← citeshttps://doi.org/10.1016/j.diabres.2024.111648openalex-snapshot
Epidemiology of NAFLD – Focus on diabetes
inferred← citeshttps://doi.org/10.1016/j.diabres.2025.112418openalex-snapshot
Association of chronic kidney disease and type 2 diabetes mellitus with metabolic dysfunction-associated steatotic liver disease and liver fibrosis assessed by transient elastography: a cross-sectional study based on NHANES 2017–2020
inferred← citeshttps://doi.org/10.1016/j.diabres.2026.113240openalex-snapshot
Gestational diabetes and subsequent risk of type 2 diabetes and metabolic dysfunction-associated steatotic liver disease in a commercially insured U.S. Pregnancy cohort
inferred← citeshttps://doi.org/10.1016/j.ecl.2022.06.007openalex-snapshot
Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1016/j.ejim.2022.03.025openalex-snapshot
Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.eprac.2022.03.010openalex-snapshot
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
inferred← citeshttps://doi.org/10.1016/j.eprac.2023.06.012openalex-snapshot
Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology Clinics
inferred← citeshttps://doi.org/10.1016/j.eprac.2025.04.021openalex-snapshot
Diagnostic Performance of Noninvasive Tests for Identifying Advanced Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease With Mixed Etiologies
inferred← citeshttps://doi.org/10.1016/j.eprac.2026.09.117openalex-snapshot
Implementing MASLD Screening in Primary Care for Adults with Type 2 Diabetes: A Quality Improvement Initiative
inferred← citeshttps://doi.org/10.1016/j.gastha.2026.100923openalex-snapshot
Cost-Effectiveness of Blood-Based Fibrosis Screening in High-Risk Metabolic Liver Diseases With Emerging Therapies
inferred← citeshttps://doi.org/10.1016/j.gastre.2022.12.010openalex-snapshot
NAFLD and type 2 diabetes: A practical guide for the joint management
inferred← citeshttps://doi.org/10.1016/j.gastrohep.2022.12.002openalex-snapshot
NAFLD and type 2 diabetes: A practical guide for the joint management
inferred← citeshttps://doi.org/10.1016/j.intimp.2023.109738openalex-snapshot
Research progress of metformin in the treatment of liver fibrosis
inferred← citeshttps://doi.org/10.1016/j.jacl.2022.03.007openalex-snapshot
JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk
inferred← citeshttps://doi.org/10.1016/j.jcjd.2025.04.003openalex-snapshot
Diabetes and Metabolic Dysfunction–associated Steatotic Liver Disease in Adults: A Clinical Practice Guideline
inferred← citeshttps://doi.org/10.1016/j.jdiacomp.2023.108405openalex-snapshot
Prevalence and clinical determinants of non-alcoholic fatty liver disease by liver scores in adults with type 1 diabetes
inferred← citeshttps://doi.org/10.1016/j.jdiacomp.2023.108525openalex-snapshot
Circulating soluble CD163 as a potential biomarker of diabetes complications
inferred← citeshttps://doi.org/10.1016/j.jdiacomp.2024.108928openalex-snapshot
Hepatic effects of GLP-1 mimetics in diabetic milieu: A mechanistic review of involved pathways
inferred← citeshttps://doi.org/10.1016/j.jgeb.2026.100733openalex-snapshot
MMP-9 and non-invasive markers in evaluating MASLD and atherosclerosis
inferred← citeshttps://doi.org/10.1016/j.jhep.2022.03.026openalex-snapshot
Impact of non-invasive biomarkers on hepatology practice: Past, present and future
inferred← citeshttps://doi.org/10.1016/j.jhep.2022.08.040openalex-snapshot
The association between liver fibrosis and cognitive impairment in type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.jhep.2022.11.010openalex-snapshot
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.jhep.2024.12.045openalex-snapshot
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
inferred← citeshttps://doi.org/10.1016/j.jhep.2025.01.026openalex-snapshot
Moving diagnosis of liver fibrosis into the community
inferred← citeshttps://doi.org/10.1016/j.jhep.2025.02.014openalex-snapshot
Personalized risk assessment of advanced liver fibrosis in patients with MASLD
inferred← citeshttps://doi.org/10.1016/j.jhepr.2021.100293openalex-snapshot
Embedding assessment of liver fibrosis into routine diabetic review in primary care
inferred← citeshttps://doi.org/10.1016/j.jhepr.2023.100925openalex-snapshot
FIB-4 and APRI for cirrhosis detection in a privately insured national cohort
inferred← citeshttps://doi.org/10.1016/j.jpba.2023.115801openalex-snapshot
Potential roles of HSYA in attenuating sepsis-induced liver injury through multi-omics analysis
inferred← citeshttps://doi.org/10.1016/j.lanepe.2025.101320openalex-snapshot
A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis
inferred← citeshttps://doi.org/10.1016/j.mayocp.2024.04.014openalex-snapshot
Management of Type 2 Diabetes Mellitus: Synopsis of the Department of Veterans Affairs and Department of Defense Clinical Practice Guideline
inferred← citeshttps://doi.org/10.1016/j.med.2024.03.014openalex-snapshot
Protocolo diagnóstico y terapéutico de la esteatosis hepática asociada a disfunción metabólica
inferred← citeshttps://doi.org/10.1016/j.medcle.2025.106981openalex-snapshot
Prevalence of liver fibrosis index-4 (FIB-4) positive results in patients with diabetes
inferred← citeshttps://doi.org/10.1016/j.medcle.2026.107536openalex-snapshot
Metabolic dysfunction-associated steatotic liver disease in the cardio-renal-metabolic syndrome: The silenced ‘H’
inferred← citeshttps://doi.org/10.1016/j.medcli.2025.106981openalex-snapshot
Prevalence of liver fibrosis index-4 (FIB-4) positive results in patients with diabetes
inferred← citeshttps://doi.org/10.1016/j.medcli.2026.107536openalex-snapshot
Esteatosis hepática metabólica en el síndrome cardio-reno-metabólico: la «H» silenciada
inferred← citeshttps://doi.org/10.1016/j.medj.2024.03.003openalex-snapshot
LiverRisk score: An accurate, cost-effective tool to predict fibrosis, liver-related, and diabetes-related mortality in the general population
inferred← citeshttps://doi.org/10.1016/j.microc.2026.117763openalex-snapshot
Molecular mechanism and metabolic abnormality detection of CYP2C19 based on electrochemical sensors: Metabolic driving factors of MASLD liver fibrosis
inferred← citeshttps://doi.org/10.1016/j.numecd.2021.06.020openalex-snapshot
Hepatic fibrosis of any origin in a large population of type 2 diabetes patients
inferred← citeshttps://doi.org/10.1016/j.nutos.2024.11.001openalex-snapshot
Religious intermittent fasting: Effects on liver health, metabolic markers, and gut microbiota in type 2 diabetes patients
inferred← citeshttps://doi.org/10.1016/j.pcd.2022.01.005openalex-snapshot
Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists?
inferred← citeshttps://doi.org/10.1016/j.rce.2022.11.007openalex-snapshot
Efecto de semaglutida sobre los biomarcadores de la enfermedad del hígado graso en pacientes con diabetes y obesidad
inferred← citeshttps://doi.org/10.1016/j.rceng.2022.12.001openalex-snapshot
Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity
inferred← citeshttps://doi.org/10.1016/j.soard.2026.05.016openalex-snapshot
Baseline Hepamet fibrosis score is associated with type 2 diabetes remission after bariatric surgery
inferred← citeshttps://doi.org/10.1016/j.tice.2026.103425openalex-snapshot
Metformin is associated with the suppression of the TNF-α/iNOS/TIMP-1 axis-mediated liver injury and fibrosis secondary to diabetes
inferred← citeshttps://doi.org/10.1016/s2213-8587(22)00003-1openalex-snapshot
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
inferred← citeshttps://doi.org/10.1016/s2468-1253(23)00157-7openalex-snapshot
Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis
inferred← citeshttps://doi.org/10.1016/s2468-1253(23)00270-4openalex-snapshot
Implementation of a liver health check in people with type 2 diabetes
inferred← citeshttps://doi.org/10.1016/s2468-1253(24)00313-3openalex-snapshot
Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study
inferred← citeshttps://doi.org/10.1038/s41569-025-01220-4openalex-snapshot
The global cardiovascular–liver–metabolic syndemic: epidemiology, trends and challenges
inferred← citeshttps://doi.org/10.1038/s41598-022-06205-8openalex-snapshot
Relationship between the dynamics of non-alcoholic fatty liver disease and incident diabetes mellitus
inferred← citeshttps://doi.org/10.1038/s41598-024-63386-0openalex-snapshot
Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study
inferred← citeshttps://doi.org/10.1038/s41598-025-10871-9openalex-snapshot
MISHTI study evaluating hepatic fibrosis in type 2 diabetes patients in India
inferred← citeshttps://doi.org/10.1039/d2mo00036aopenalex-snapshot
Metabolomics study reveals the alteration of fatty acid oxidation in the hearts of diabetic mice by empagliflozin
inferred← citeshttps://doi.org/10.1053/j.gastro.2021.07.049openalex-snapshot
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1053/j.gastro.2023.04.025openalex-snapshot
Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study
inferred← citeshttps://doi.org/10.1053/j.gastro.2023.05.053openalex-snapshot
Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China
inferred← citeshttps://doi.org/10.1053/j.gastro.2026.01.047openalex-snapshot
Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1053/j.jvca.2022.06.028openalex-snapshot
Preoperative Liver Stiffness is Associated With Hospital Length of Stay After Cardiac Surgery
inferred← citeshttps://doi.org/10.1055/a-2082-5203openalex-snapshot
Screening for At-Risk Nonalcoholic Fatty Liver Disease in the Primary Care Setting
inferred← citeshttps://doi.org/10.1055/s-0042-1751081openalex-snapshot
Noninvasive Algorithms for the Case Finding of “At-Risk” Patients with NAFLD
inferred← citeshttps://doi.org/10.1055/s-0043-1770984openalex-snapshot
How to Identify Advanced Nonalcoholic Fatty Liver Disease in the Primary Care Setting
inferred← citeshttps://doi.org/10.1056/nejme2314365openalex-snapshot
Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH
inferred← citeshttps://doi.org/10.1080/17446651.2023.2248242openalex-snapshot
Identification of individuals at risk of hepatocellular carcinoma: screening for clinically significant liver fibrosis in patients with T2DM
inferred← citeshttps://doi.org/10.1093/ajhp/zxaf251openalex-snapshot
Pharmacist-led screening for advanced fibrosis using the FIB-4 index in patients 65 years or older with a clinical suspicion for MASLD at a family medicine clinic
inferred← citeshttps://doi.org/10.1093/alcalc/agag011openalex-snapshot
Increases in binge and heavy drinking frequencies during the COVID-19 pandemic are associated with liver fibrosis
inferred← citeshttps://doi.org/10.1093/eurheartj/ehad445openalex-snapshot
Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table
inferred← citeshttps://doi.org/10.1093/fampra/cmag008openalex-snapshot
Can the Finnish Diabetes Risk Score (FINDRISC) be used to predict liver fibrosis risk instead of the fibrosis-4 index (FIB-4)?
inferred← citeshttps://doi.org/10.1097/hc9.0000000000000024openalex-snapshot
Prospective study of a case-finding algorithm to detect NAFLD with advanced fibrosis in primary care patients
inferred← citeshttps://doi.org/10.1097/hep.0000000000000263openalex-snapshot
Diabetes and cirrhosis: Current concepts on diagnosis and management
inferred← citeshttps://doi.org/10.1097/hep.0000000000000323openalex-snapshot
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1097/hep.0000000000000356openalex-snapshot
Predicting liver-related events in NAFLD: A predictive model
inferred← citeshttps://doi.org/10.1097/js9.0000000000001872openalex-snapshot
Effect of metformin on hepatocellular carcinoma patients with type II diabetes receiving transarterial chemoembolization: a multicenter retrospective cohort study
inferred← citeshttps://doi.org/10.1097/js9.0000000000002680openalex-snapshot
Integrated network toxicology and population-based analysis uncovers organophosphate flame retardant exposure as a risk factor for hepatic steatosis and fibrosis: mechanistic and clinical insights
inferred← citeshttps://doi.org/10.1097/mcg.0000000000001780openalex-snapshot
Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis
inferred← citeshttps://doi.org/10.1097/mcg.0000000000002321openalex-snapshot
Cannabis Use in Metabolic Dysfunction-Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1097/md.0000000000042016openalex-snapshot
The accuracy of FibroScan, FIB-4, and nonalcoholic fatty liver disease fibrosis score in predicting biopsy-defined fibrosis and steatosis across all fibrosis stages in patients with metabolic dysfunction associated steatotic liver disease
inferred← citeshttps://doi.org/10.1097/ms9.0000000000001875openalex-snapshot
The interplay between diabetes and non-alcoholic fatty liver disease: a cross-sectional study from Pakistan
inferred← citeshttps://doi.org/10.1097/ms9.0000000000004012openalex-snapshot
Diabetes and liver cirrhosis: shared pathways and clinical implications – a narrative review
inferred← citeshttps://doi.org/10.1111/1751-2980.13325openalex-snapshot
Type 2 Diabetes and Hypertension as Risk Factors for Advanced Fibrosis in Biopsy Proven Metabolic Dysfunction–Associated Steatotic Liver Disease
inferred← citeshttps://doi.org/10.1111/apt.17385openalex-snapshot
Meta‐analysis: Enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases
inferred← citeshttps://doi.org/10.1111/apt.70020openalex-snapshot
Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis ( MASH ): From the Growing Prevalence to Payors' Perspective
inferred← citeshttps://doi.org/10.1111/ctr.15437openalex-snapshot
Graft Steatosis and Donor Diabetes Mellitus Additively Impact on Recipient Outcomes After Liver Transplantation—A European Registry Study
inferred← citeshttps://doi.org/10.1111/dme.14912openalex-snapshot
Banting memorial lecture 2022: ‘Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime’
inferred← citeshttps://doi.org/10.1111/dom.14651openalex-snapshot
The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
inferred← citeshttps://doi.org/10.1111/dom.15016openalex-snapshot
Nonalcoholic fatty liver disease from a primary care perspective
inferred← citeshttps://doi.org/10.1111/dom.15758openalex-snapshot
Impact of non‐alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi‐cohort longitudinal study
inferred← citeshttps://doi.org/10.1111/dom.16065openalex-snapshot
Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
inferred← citeshttps://doi.org/10.1111/dom.70156openalex-snapshot
Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetes
inferred← citeshttps://doi.org/10.1111/dom.70398openalex-snapshot
Spatiotemporal burden, risk factors, and genetic causality of non‐alcoholic fatty liver disease and type 2 diabetes mellitus comorbidity in Europe: A multi‐database analysis
inferred← citeshttps://doi.org/10.1111/dom.70820openalex-snapshot
Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis
inferred← citeshttps://doi.org/10.1111/fcp.12897openalex-snapshot
FTY‐720 alleviates diabetes‐induced liver injury by inhibiting oxidative stress and inflammation
inferred← citeshttps://doi.org/10.1111/jdi.13756openalex-snapshot
Non‐alcoholic fatty liver disease and type 2 diabetes: An update
inferred← citeshttps://doi.org/10.1111/jdi.70112openalex-snapshot
A nomogram incorporating clinical and laboratory indicators for predicting metabolic dysfunction‐associated fatty liver disease in newly diagnosed type 2 diabetes patients
inferred← citeshttps://doi.org/10.1111/jgh.16240openalex-snapshot
Evaluation of blood‐based PRO‐C3 testing as a diagnostic marker for staging liver fibrosis: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1111/jvh.13808openalex-snapshot
A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD
inferred← citeshttps://doi.org/10.1111/liv.15259openalex-snapshot
Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction‐associated fatty liver disease in Korea
inferred← citeshttps://doi.org/10.1111/nyas.15012openalex-snapshot
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
inferred← citeshttps://doi.org/10.1111/nyas.15259openalex-snapshot
Diabetes and cardiovascular disease in older adults
inferred← citeshttps://doi.org/10.1111/wrr.13108openalex-snapshot
Cutaneous changes in diabetic patients: Primed for aberrant healing?
inferred← citeshttps://doi.org/10.1136/bmjdrc-2026-005947openalex-snapshot
Reduced circulating Mig-6 levels are associated with dysglycemia in metabolic dysfunction associated steatotic liver disease (MASLD)
inferred← citeshttps://doi.org/10.1136/bmjgast-2021-000638openalex-snapshot
Uncovering undiagnosed liver disease: prevalence and opportunity for intervention in a population attending colonoscopy
inferred← citeshttps://doi.org/10.1136/bmjgast-2024-001466openalex-snapshot
Forns index and fatty liver index, but not FIB-4, are associated with indices of glycaemia, pre-diabetes and type 2 diabetes: analysis of The Maastricht Study
inferred← citeshttps://doi.org/10.1136/bmjmed-2022-000372openalex-snapshot
Advances in the management of type 2 diabetes in adults
inferred← citeshttps://doi.org/10.1136/bmjopen-2022-063959openalex-snapshot
Identification of patients with type 2 diabetes with non-alcoholic fatty liver disease who are at increased risk of progressing to advanced fibrosis: a cross-sectional study
inferred← citeshttps://doi.org/10.1136/bmjopen-2023-080549openalex-snapshot
Risk-stratified hepatocellular carcinoma screening according to the degree of obesity and progression to cirrhosis for diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Japan: a cost-effectiveness study
inferred← citeshttps://doi.org/10.1136/bmjopen-2024-087550openalex-snapshot
Prevalence and characteristics of liver steatosis and fibrosis in type 2 diabetes mellitus (T2DM) patients: a cross-sectional study in populations of eastern China
inferred← citeshttps://doi.org/10.1136/bmjopen-2024-088043openalex-snapshot
Screening to identify people with type 2 diabetes at risk of liver cancer in primary care: a randomised controlled trial protocol
inferred← citeshttps://doi.org/10.1136/egastro-2023-100015openalex-snapshot
Mechanisms of liver fibrosis in metabolic syndrome
inferred← citeshttps://doi.org/10.1136/flgastro-2024-102856openalex-snapshot
Role of anti-diabetic medications in the management of MASLD
inferred← citeshttps://doi.org/10.1136/gutjnl-2023-330110openalex-snapshot
Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1136/gutjnl-2023-330269openalex-snapshot
Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial
inferred← citeshttps://doi.org/10.1148/radiol.233410openalex-snapshot
Automated Comprehensive CT Assessment of the Risk of Diabetes and Associated Cardiometabolic Conditions
inferred← citeshttps://doi.org/10.1148/radiol.250026openalex-snapshot
Liver MRI–derived Proton Density Fat Fraction Predicts Diabetes Risk in Patients with Obesity: A Dose-Response Study
inferred← citeshttps://doi.org/10.1155/2022/8429847openalex-snapshot
Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center
inferred← citeshttps://doi.org/10.1155/2023/3803056openalex-snapshot
The PTP1B Inhibitor Trodusquemine (MSI-1436) Improves Glucose Uptake in Equine Metabolic Syndrome Affected Liver through Anti-Inflammatory and Antifibrotic Activity
inferred← citeshttps://doi.org/10.1155/2024/8877130openalex-snapshot
The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study
inferred← citeshttps://doi.org/10.11569/wcjd.v33.i2.122openalex-snapshot
Potential association of neutrophil-albumin ratio with non-alcoholic fatty liver disease: A cross-sectional study based on NHANES
inferred← citeshttps://doi.org/10.1159/000527595openalex-snapshot
Obesity-Induced Hepatic Steatosis Is Partly Mediated by Visceral Fat Accumulation in Subjects with Overweight/Obesity: A Cross-Sectional Study
inferred← citeshttps://doi.org/10.1177/15578518251377780openalex-snapshot
Triglyceride Glucose Index and Related Parameters Are Effective Biomarkers to Identify Metabolic Dysfunction-Associated Steatotic Liver Disease Among Egyptian Adults with Type 2 Diabetes
inferred← citeshttps://doi.org/10.1177/20503121241292678openalex-snapshot
Non-alcoholic fatty liver disease among people living with HIV on long-term antiretroviral therapy in Indonesia: Prevalence and related factors
inferred← citeshttps://doi.org/10.1177/2633559x231213071openalex-snapshot
Preventing and Treating Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 2 Diabetes: Promising Therapeutic Agents and Strategies
inferred← citeshttps://doi.org/10.1177/30502071231220779openalex-snapshot
Diagnosis and Management of MASLD: An Metabolic Perspective of a Multisystem Disease
inferred← citeshttps://doi.org/10.1182/bloodadvances.2024013750openalex-snapshot
Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice
inferred← citeshttps://doi.org/10.1186/s12875-025-03039-xopenalex-snapshot
Prevalence of advanced fibrosis risk using FIB-4 in patients with type 2 diabetes and its associated factors: a cross-sectional study in a primary care unit of a university hospital in Southern Thailand
inferred← citeshttps://doi.org/10.1186/s12876-022-02550-0openalex-snapshot
Association between hepatic steatosis and fibrosis with measures of insulin sensitivity in patients with severe obesity and type 2 diabetes - a cross-sectional study
inferred← citeshttps://doi.org/10.1186/s12876-023-03007-8openalex-snapshot
Triglyceride glucose-waist circumference: the optimum index to screen nonalcoholic fatty liver disease in non-obese adults
inferred← citeshttps://doi.org/10.1186/s12876-025-03612-9openalex-snapshot
Association between neutrophil-albumin ratio and ultrasound-defined metabolic dysfunction-associated fatty liver disease in U.S. adults: evidence from NHANES 2017–2018
inferred← citeshttps://doi.org/10.1186/s12876-025-03850-xopenalex-snapshot
Machine learning-based disease risk stratification and prediction of metabolic dysfunction-associated fatty liver disease using vibration-controlled transient elastography: Result from NHANES 2021–2023
inferred← citeshttps://doi.org/10.1186/s12876-025-03917-9openalex-snapshot
Gender difference in the association between serum uric acid and metabolic dysfunction-associated steatotic liver disease in patients with newly diagnosed type 2 diabetes
inferred← citeshttps://doi.org/10.1186/s12880-024-01531-xopenalex-snapshot
Liver fibrosis stage classification in stacked microvascular images based on deep learning
inferred← citeshttps://doi.org/10.1186/s12902-022-01046-yopenalex-snapshot
Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ≥ 40 years
inferred← citeshttps://doi.org/10.1186/s12913-022-07808-7openalex-snapshot
Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes
inferred← citeshttps://doi.org/10.1186/s12933-023-02049-2openalex-snapshot
Plasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes
inferred← citeshttps://doi.org/10.1186/s12944-025-02849-3openalex-snapshot
Abnormal lipid profile in the context of liver steatosis measured by transient elastography: experiences from an outpatient endocrine clinic
inferred← citeshttps://doi.org/10.1186/s40001-025-03594-0openalex-snapshot
A nomogram for assessing the risk of MAFLD based on the albumin-to-gamma-glutamyl transferase ratio
inferred← citeshttps://doi.org/10.1186/s41043-026-01241-wopenalex-snapshot
Pilot study on the effectiveness of the traditional Karlovy Vary thermal spring drinking cure in the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD)
inferred← citeshttps://doi.org/10.1186/s43066-024-00387-8openalex-snapshot
Diagnostic and prognostic value of plasma lipocalin-2 levels in patients with metabolic dysfunction–associated steatotic liver disease
inferred← citeshttps://doi.org/10.1186/s43066-025-00419-xopenalex-snapshot
Serum Mac-2 binding protein glycosylation isomer as a biomarker for metabolic dysfunction associated steatotic liver disease
inferred← citeshttps://doi.org/10.1210/clinem/dgab578openalex-snapshot
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
inferred← citeshttps://doi.org/10.1210/clinem/dgac382openalex-snapshot
Fibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients
inferred← citeshttps://doi.org/10.1210/clinem/dgac624openalex-snapshot
Approach to the Patient With Nonalcoholic Fatty Liver Disease
inferred← citeshttps://doi.org/10.1210/clinem/dgac660openalex-snapshot
Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD
inferred← citeshttps://doi.org/10.1210/clinem/dgag042openalex-snapshot
Severity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes
showing the first 200 of 351 · page through all 351
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.